glioblastoma
A recent study showed that the firm's technology could predict glioblastoma patients' chemo responses as well or better than an established genomic biomarker.
Mustang Bio Initiates CAR T-Cell Therapy in Phase I Brain Tumor Trial
The trial will enroll up to 30 patients with leptomeningeal brain tumors, including glioblastoma, ependymoma, or medulloblastoma.
Berg Advances BPM31510, Applies AI Platform to Biomarker Search in Phase II Brain Cancer Trial
Premium
The firm will collect multi-omics data from GBM patients and use its AI platform to home in on biomarkers of response to BPM31510.
Glioblastoma Transcriptomes Point to Mitochondrial Subtype, Potential Treatment Strategies
Using single-cell and bulk RNA sequence data, investigators identified four pathway-based GBM subtypes, including a mitochondrial subtype that appears to respond to related inhibitors.
Denovo Begins Phase III Glioblastoma Trial of Enzastaurin
The firm is evaluating enzastaurin plus chemo and radiation in glioblastoma patients with a biomarker, dubbed de novo genomic marker 1.